Clinical proof of concept for a safe and effective NF-kappaB-targeting strategy in multiple myeloma(77 visite) Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G
Impact factor: 4.498, Impact factor a 5 anni: 4.875
Url: Non disponibile.
Parole chiave: Nf-Kappab, Apoptosis, Clinical Trials, Drug, Multiple Myeloma,
*** IBB - CNR *** CCSI, Department of Medicine, Imperial College London, London, UK., Cancer Research UK Centre for Drug Development, London, UK., C&C Management Consulting Ltd, Exmouth, UK., Alpha Preclinical Consultancy, Halifax, UK., Independent Consultant, Royston, UK., In2Phase Ltd, Welwyn Garden City, UK., Department of Molecular Medicine, University of Naples Federico II, Naples, Italy., IBB-CNR and CIRPeB, "Federico II" University of Naples, Naples, Italy., Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy., DiSTABiF, University of Campania "Luigi Vanvitelli", Caserta, Italy., West Middlesex University Hospital, Isleworth, Greater London, UK., Haematology Department, Chelsea and Westminster Hospital, London, UK., London Haematology Limited, London, UK., Barts Cancer Centre, St Bartholomew's Hospital London, London, UK., Division of Molecular Pathology, The Institute of Cancer Research, London, UK., Royal Free London NHS Foundation Trust, London, UK., Department of Haematology, King's College Hospital, London, UK., Centre for Haematology, Imperial College London, London, UK., Cancer Cell Protein Metabolism, Department of Medicine, Imperial College London, London, UK.,